Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 558

1.

Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial.

Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N.

Am J Kidney Dis. 2009 Oct;54(4):647-52. doi: 10.1053/j.ajkd.2009.04.036. Epub 2009 Jul 12.

PMID:
19596163
2.

Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.

Greenbaum LA, Benador N, Goldstein SL, Paredes A, Melnick JZ, Mattingly S, Amdahl M, Williams LA, Salusky IB.

Am J Kidney Dis. 2007 Jun;49(6):814-23.

PMID:
17533024
3.

Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2.

Llach F, Keshav G, Goldblat MV, Lindberg JS, Sadler R, Delmez J, Arruda J, Lau A, Slatopolsky E.

Am J Kidney Dis. 1998 Oct;32(2 Suppl 2):S48-54.

PMID:
9808143
4.

Oral calcitriol for reduction of proteinuria in patients with IgA nephropathy: a randomized controlled trial.

Liu LJ, Lv JC, Shi SF, Chen YQ, Zhang H, Wang HY.

Am J Kidney Dis. 2012 Jan;59(1):67-74. doi: 10.1053/j.ajkd.2011.09.014. Epub 2011 Oct 22.

PMID:
22019331
5.

Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.

Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM.

Am J Nephrol. 2008;28(1):97-106. Epub 2007 Oct 3.

PMID:
17914251
6.

Paricalcitol reduces proteinuria but does not modify peritoneal protein loss in patients on peritoneal dialysis.

Sánchez-Álvarez JE, Rodríguez-Suárez C, Coronel-Aguilar D, González-Díaz I, Núñez-Moral M, Peláez-Requejo B, Fernández-Viña A, Quintana-Fernández A.

Nefrologia. 2013 Jan 18;33(1):70-6. doi: 10.3265/Nefrologia.pre2012.Oct.11635. English, Spanish.

7.

Oral paricalcitol as antiproteinuric agent in chronic kidney disease.

de Lorenzo A, Salanova L, Bomback AS, Moya M, Coronel F, Bernis C, Sánchez-Tomero JA, Álvarez V.

Nefrologia. 2013;33(5):709-15. doi: 10.3265/Nefrologia.pre2013.Jun.11928.

8.

Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.

Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, Fadem S, Levine B, Williams L, Andress DL, Sprague SM.

Am J Kidney Dis. 2006 Feb;47(2):263-76.

PMID:
16431255
9.

The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.

Esnault VL, Brown EA, Apetrei E, Bagon J, Calvo C, DeChatel R, Holdaas H, Krcmery S, Kobalava Z; Amlodipine Versus Enalapril in Renal failure (AVER) Study Group.

Clin Ther. 2008 Mar;30(3):482-98. doi: 10.1016/j.clinthera.2008.03.006.

PMID:
18405787
10.

Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.

Zisman AL, Hristova M, Ho LT, Sprague SM.

Am J Nephrol. 2007;27(1):36-43. Epub 2007 Jan 11.

PMID:
17215573
11.

Antiproteinuric effect of oral paricalcitol in chronic kidney disease.

Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, Williams L, Batlle D.

Kidney Int. 2005 Dec;68(6):2823-8.

12.

Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial.

Perkins RM, Aboudara MC, Uy AL, Olson SW, Cushner HM, Yuan CM.

Am J Kidney Dis. 2009 Apr;53(4):606-16. doi: 10.1053/j.ajkd.2008.11.026. Epub 2009 Feb 12.

PMID:
19216016
13.

Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial.

Lin SL, Chen YM, Chiang WC, Wu KD, Tsai TJ.

Am J Kidney Dis. 2008 Sep;52(3):464-74. doi: 10.1053/j.ajkd.2008.05.012. Epub 2008 Jul 9.

PMID:
18617301
14.

Paricalcitol reduces proteinuria in non-dialysis chronic kidney disease patients.

Hojs N, Bevc S, Balon BP, Hojs R, Ekart R.

Ther Apher Dial. 2013 Aug;17(4):368-72. doi: 10.1111/1744-9987.12080.

PMID:
23931873
15.

Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters.

Matias PJ, Jorge C, Ferreira C, Borges M, Aires I, Amaral T, Gil C, Cortez J, Ferreira A.

Clin J Am Soc Nephrol. 2010 May;5(5):905-11. doi: 10.2215/CJN.06510909. Epub 2010 Mar 4.

16.

Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4.

Coburn JW, Maung HM, Elangovan L, Germain MJ, Lindberg JS, Sprague SM, Williams ME, Bishop CW.

Am J Kidney Dis. 2004 May;43(5):877-90.

PMID:
15112179
18.

Paricalcitol for secondary hyperparathyroidism in renal transplantation.

Trillini M, Cortinovis M, Ruggenenti P, Reyes Loaeza J, Courville K, Ferrer-Siles C, Prandini S, Gaspari F, Cannata A, Villa A, Perna A, Gotti E, Caruso MR, Martinetti D, Remuzzi G, Perico N.

J Am Soc Nephrol. 2015 May;26(5):1205-14. doi: 10.1681/ASN.2013111185. Epub 2014 Sep 5.

19.

Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD.

Al-Aly Z, Qazi RA, González EA, Zeringue A, Martin KJ.

Am J Kidney Dis. 2007 Jul;50(1):59-68.

PMID:
17591525
20.

Calcium balance during calcitriol and paricalcitol administration in healthy humans.

Hafner V, Rutsch C, Ding R, Heinrich T, Diedrichs L, Schmidt-Gayk H, Walter-Sack I, Bommer J, Mikus G.

Int J Clin Pharmacol Ther. 2008 Mar;46(3):131-5.

PMID:
18397683

Supplemental Content

Support Center